Colgate-Palmolive (CL) Reports Q1 Earnings: What Key Metrics Have to Say

25.04.25 15:30 Uhr

Werte in diesem Artikel
Aktien

82,43 EUR 1,01 EUR 1,24%

Indizes

PKT PKT

16.240,1 PKT 197,2 PKT 1,23%

2.679,8 PKT 29,0 PKT 1,10%

5.525,2 PKT 40,4 PKT 0,74%

Colgate-Palmolive (CL) reported $4.91 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3%. EPS of $0.91 for the same period compares to $0.86 a year ago.The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $4.86 billion. With the consensus EPS estimate being $0.86, the EPS surprise was +5.81%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Oral, Personal and Home Care- North America: $998 million versus $1 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change. Net Sales- Oral, Personal and Home Care- Latin America: $1.14 billion compared to the $1.09 billion average estimate based on six analysts. The reported number represents a change of -8.8% year over year. Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $271 million compared to the $273.66 million average estimate based on six analysts. The reported number represents a change of -1.8% year over year. Net Sales- Oral, Personal and Home Care- Europe: $690 million versus the six-analyst average estimate of $674.15 million. The reported number represents a year-over-year change of -3%. Net Sales- Oral, Personal and Home Care- Asia Pacific: $690 million versus the six-analyst average estimate of $727.36 million. The reported number represents a year-over-year change of -5.1%. Net Sales- Pet Nutrition: $1.12 billion versus the six-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of +1.5%. Net Sales- Total Oral, Personal and Home Care: $3.79 billion versus the six-analyst average estimate of $3.77 billion. The reported number represents a year-over-year change of -4.3%. Operating profit- Total Oral, Personal and Home Care: $971 million versus $1.01 billion estimated by four analysts on average. Operating profit- Corporate: -$153 million versus the four-analyst average estimate of -$182.49 million. Operating profit- Pet Nutrition: $258 million compared to the $239.30 million average estimate based on four analysts. View all Key Company Metrics for Colgate-Palmolive here>>>Shares of Colgate-Palmolive have returned -0.5% over the past month versus the Zacks S&P 500 composite's -4.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Colgate-Palmolive und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Colgate-Palmolive

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Colgate-Palmolive

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Colgate-Palmolive Co.

Wer­bung

Analysen zu Colgate-Palmolive Co.

DatumRatingAnalyst
14.12.2017Colgate-Palmolive HoldDeutsche Bank AG
30.01.2017Colgate-Palmolive HoldStifel, Nicolaus & Co., Inc.
28.10.2016Colgate-Palmolive NeutralB. Riley & Co., LLC
28.10.2016Colgate-Palmolive NeutralUBS AG
29.04.2016Colgate-Palmolive NeutralUBS AG
DatumRatingAnalyst
30.01.2017Colgate-Palmolive HoldStifel, Nicolaus & Co., Inc.
17.10.2014Colgate-Palmolive Market PerformBMO Capital Markets
11.12.2012Colgate-Palmolive overweightHSBC
26.11.2012Colgate-Palmolive kaufenDie Actien-Börse
18.10.2011Colgate-Palmolive overweightMorgan Stanley
DatumRatingAnalyst
14.12.2017Colgate-Palmolive HoldDeutsche Bank AG
28.10.2016Colgate-Palmolive NeutralB. Riley & Co., LLC
28.10.2016Colgate-Palmolive NeutralUBS AG
29.04.2016Colgate-Palmolive NeutralUBS AG
04.01.2016Colgate-Palmolive Sector PerformRBC Capital Markets
DatumRatingAnalyst
05.01.2005Update Colgate-Palmolive Co.: SellBanc of America Sec.
05.01.2005Update Colgate-Palmolive Co.: SellBanc of America Sec.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Colgate-Palmolive Co. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen